The European Commission (EC) has taken an European Union-wide legally binding decision and confirmed the favorable benefit/risk profile of ambroxol and bromhexine containing medicines. This decision follows the opinion of the Coordination Group for Mutual Recognition and Decentralized Procedures–Human (CMDh) as well as the recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) within the European Medicines Agency (EMA).
Sanofi is in exclusive talks to swap assets with Germany’s Boehringer Ingelheim GmbH in a 22.8 billion-euro ($25 billion) transaction that would be the largest for the French drugmaker in more than a decade.
Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.
Ambroxol and Bromhexine Expectorants: Safety Information to Be Updated